Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX4 | Q99571 | 20/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16238995 | 1.00 | P2RX4 (0.70) | P2RX4 | |
| SCHEMBL30297407 | 0.94 | P2RX4 (0.67) | P2RX4 | |
| SCHEMBL16239502 | 0.94 | P2RX4 (0.67) | P2RX4 | |
| SCHEMBL30297447 | 0.90 | P2RX4 (0.74) | P2RX4 | |
| SCHEMBL16239174 | 0.90 | P2RX4 (0.74) | P2RX4 | |
| SCHEMBL16239133 | 0.90 | P2RX4 (0.66) | P2RX4 | |
| SCHEMBL30229672 | 0.89 | P2RX4 (0.72) | P2RX4 | |
| SCHEMBL16239170 | 0.89 | P2RX4 (0.72) | P2RX4 | |
| SCHEMBL16239705 | 0.88 | P2RX4 (0.71) | P2RX4 | |
| SCHEMBL30297436 | 0.88 | P2RX4 (0.71) | P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | NIPPON CHEMIPHAR CO., LTD. (JP) | 2026-05-19 | — | — | US | claimed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | claimed |
| EP-4408432-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-07 | — | — | EP | claimed |
| CN-118176003-A | Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain | 日本化学药品株式会社 | 2024-06-11 | — | — | CN | claimed |
| CN-118019551-A | Preventive or therapeutic agent for respiratory diseases | 日本化学药品株式会社 | 2024-05-10 | — | — | CN | claimed |
| WO-2023052518-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2023-04-06 | — | — | WO | claimed |
| EP-4129296-A1 | DRUG FOR PREVENTION OR TREATMENT OF IRRITABLE BOWEL SYNDROME OR INFLAMMATORY BOWEL DISEASE | Università di Pisa (IT) | 2023-02-08 | — | — | EP | claimed |
| EP-4501357-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | Takasaki University of Health and Welfare (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-119233829-A | Pharmaceutical composition for preventing, inhibiting or treating symptoms associated with pseudoallergy | 学校法人高崎健康福祉大学 | 2024-12-31 | — | — | CN | disclosed |
| US-12090158-B2 | Medicine for diabetic peripheral neuropathy | NIPPON CHEMIPHAR CO., LTD. (JP) | 2024-09-17 | — | — | US | disclosed |
| EP-4408432-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410310-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES | Nippon Chemiphar Co., Ltd. (JP) | 2024-08-07 | — | — | EP | disclosed |
| CN-118176003-A | Medicaments comprising P2X4 receptor antagonists for the prevention or treatment of nociceptive pain and/or visceral pain | 日本化学药品株式会社 | 2024-06-11 | — | — | CN | disclosed |
| CN-118019551-A | Preventive or therapeutic agent for respiratory diseases | 日本化学药品株式会社 | 2024-05-10 | — | — | CN | disclosed |
| WO-2023190826-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR SUPPRESSING OR TREATING SYMPTOMS ACCOMPANYING PSEUDO-ALLERGIC REACTIONS | 学校法人 高崎健康福祉大学 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023157895-A1 | PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR ENDOMETRIOSIS OR ADENOMYOSIS | 国立大学法人 鳥取大学 | 2023-08-24 | — | — | WO | disclosed |
| EP-4190356-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING, SUPPRESSING, OR TREATING SYMPTOMS ASSOCIATED WITH ALLERGIC REACTION | Nippon Chemiphar Co., Ltd. (JP) | 2023-06-07 | — | — | EP | disclosed |
| WO-2023054578-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR RESPIRATORY DISEASES | 日本ケミファ株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023052518-A1 | MEDICAMENT COMPRISING A P2X4 RECEPTOR ANTAGONIST FOR PREVENTING OR TREATING NOCICEPTIVE PAIN AND/OR VISCERAL PAIN | UNIVERSITA' DEGLI STUDI DI FIRENZE (IT) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12090158-B2 | Medicine for diabetic peripheral neuropathy | P2RX4, P2RX3, P2RX1 | P2RX4 1/4885 |
| US-12629379-B2 | Pharmaceutical composition for preventing, suppressing, or treating symptom associated with allergic reaction | HRH2, HRH4, HRH1 | P2RX4 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.